The 36-month beta value for PYXS is at 1.18. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PYXS is 44.02M, and currently, shorts hold a 14.70% of that float. The average trading volume for PYXS on June 19, 2025 was 475.84K shares.
PYXS) stock’s latest price update
Pyxis Oncology Inc (NASDAQ: PYXS)’s stock price has decreased by -4.20 compared to its previous closing price of 1.19. However, the company has seen a -10.94% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-15 that – Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death
PYXS’s Market Performance
Pyxis Oncology Inc (PYXS) has seen a -10.94% fall in stock performance for the week, with a -7.32% decline in the past month and a 6.54% surge in the past quarter. The volatility ratio for the week is 2.09%, and the volatility levels for the past 30 days are at 4.04% for PYXS. The simple moving average for the past 20 days is -8.14% for PYXS’s stock, with a -43.33% simple moving average for the past 200 days.
Analysts’ Opinion of PYXS
Stephens, on the other hand, stated in their research note that they expect to see PYXS reach a price target of $13. The rating they have provided for PYXS stocks is “Overweight” according to the report published on November 08th, 2024.
Stifel gave a rating of “Buy” to PYXS, setting the target price at $10 in the report published on August 08th of the previous year.
PYXS Trading at 0.38% from the 50-Day Moving Average
After a stumble in the market that brought PYXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.85% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PYXS starting from HUMPHREY RACHEL, who proposed sale 13,896 shares at the price of $1.03 back on Apr 21 ’25. After this action, HUMPHREY RACHEL now owns shares of Pyxis Oncology Inc, valued at $14,362 using the latest closing price.
HUMPHREY RACHEL, the Director of Pyxis Oncology Inc, proposed sale 200 shares at $0.97 during a trade that took place back on Apr 17 ’25, which means that HUMPHREY RACHEL is holding shares at $194 based on the most recent closing price.
Stock Fundamentals for PYXS
Current profitability levels for the company are sitting at:
- -31.38 for the present operating margin
- 0.33 for the gross margin
The net margin for Pyxis Oncology Inc stands at -27.99. The total capital return value is set at -0.88. Equity return is now at value -66.30, with -53.49 for asset returns.
Based on Pyxis Oncology Inc (PYXS), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -3.0.
Currently, EBITDA for the company is -65.51 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 22.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.75.
Conclusion
In conclusion, Pyxis Oncology Inc (PYXS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
